StockData
Contineum Therapeutics, Inc. logo

Contineum Therapeutics, Inc. (CTNM) stock

CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$9.24−0.31 (-3.25%)

Close on Nov 18, 2026Market cap $347.62MP/E –Yield –

Contineum Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Contineum Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$53.46M. For fiscal 2025 it was -$55.54M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$55.54M–
FY2024Dec 31, 2024-$33.36M-276.2%
FY2023Dec 31, 2023$18.94M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$11.51M–
Q1 FY2026Mar 31, 2026-$16.58M–
Q4 FY2025Dec 31, 2025-$13.08M–
Q3 FY2025Sep 30, 2025-$12.30M–
Q2 FY2025Jun 30, 2025-$15.71M–
Q1 FY2025Mar 31, 2025-$14.46M–
Q4 FY2024Dec 31, 2024-$10.37M–
Q3 FY2024Sep 30, 2024-$6.25M–
Q2 FY2024Jun 30, 2024-$8.62M-121.2%
Q1 FY2024Mar 31, 2024-$8.12M–
Q4 FY2023Dec 31, 2023-$11.01M–
Q3 FY2023Sep 30, 2023-$5.40M–
Q2 FY2023Jun 30, 2023$40.64M–
Q1 FY2023Mar 31, 2023-$5.30M–

More Contineum Therapeutics figures

See a number that looks wrong?